Bluejay Diagnostics Overview
Latest ROE for Bluejay Diagnostics: -165.1% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-165.10%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for BJDX is -165.1%. That is below the sector sector average of -4.47%. Investors often review this figure alongside Bluejay Diagnostics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, BJDX currently prints -165.1% for ROE, while the sector average sits near -4.47%. That is roughly 3594.9% below the sector mean. Large gaps often invite a closer look at Bluejay Diagnostics's growth, margins, and balance sheet.
Return on Equity shows how effectively Bluejay Diagnostics converts resources into returns. At -165.1%, BJDX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting BJDX's ROE (-165.1%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
